Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. INTC
2. SPCX
3. DSX
4. GNK
5. SAN
6. TTEC
7. SNY
8. DAL
9. AWK
10. MDA

Go back to Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
EMERGENT BIOSOLUTIONS, Inc. (NYSE: EBS) Delayed: 8.00 -0.14 (1.72%)
Previous Close $8.14    52 Week High $44.38 
Open $8.22    52 Week Low $24.47 
Day High $8.32    P/E 400.00 
Day Low $7.90    EPS $0.02 
Volume 2,229,025       

(NASDAQ: SABS) Delayed: 4.00 +0.14 (3.63%)
Previous Close $3.86    52 Week High $ 
Open $3.93    52 Week Low $ 
Day High $4.10    P/E N/A 
Day Low $3.85    EPS $ 
Volume 2,908,295